clinical trial · NCT04873362
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Hoffmann-La Roche·phase3·active not recruiting·n = 1,188
Breast CancerAtezolizumabTrastuzumab EmtansinePlaceboTrastuzumab
brief summary
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have received preoperative chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a finding of residual invasive disease in the breast and/or axillary lymph nodes. As of June 4, 2024, this study is no longer accepting any newly screened participants.
started
May 4, 2021
primary completion
Aug 31, 2028
completion
Oct 2, 2034
last updated
Mar 4, 2026
official title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol